期刊文献+

熊去氧胆酸治疗原发性胆汁性肝硬化临床观察 被引量:3

下载PDF
导出
摘要 目的观察熊去氧胆酸治疗原发性胆汁性肝硬化的临床疗效。方法20例原发性胆汁性肝硬化患者,抗线粒体抗体(AMA)和抗线粒体抗体-M2(AMA—M2)均阳性,经熊去氧胆酸持续治疗时间0.5~5年(平均1.8年),观察临床表现,肝功能生化指标血清丙氨酸氨基转移酶(AIT)、天门冬氨酸氨基转移酶(AST)、白蛋白(Alb)、总胆红素(TBil)、碱性磷酸酶(AKP)和r-谷氨酰转酞酶(r—CT)等变化。结果所有患者经熊去氧胆酸治疗后,临床症状明显改善,肝功能ALT、AST、TBil、AKP和r—GT明显下降(均P〈0.01),Alb升高(P〈0.01)。患者在治疗中无明显药物不良反应和死亡发生。结论熊去氧胆酸长期治疗原发性胆汁性肝硬化,能有效减轻和控制症状,改善肝功能生化指标,减缓病情进展。
作者 周建方
机构地区 湖州市中心医院
出处 《浙江实用医学》 2006年第4期246-247,共2页 Zhejiang Practical Medicine
  • 相关文献

参考文献4

二级参考文献36

  • 1[1]Walker JG, Doniach D, Roitt IM, et al. Serological tests in the diagnosis of primary biliary cirrhosis. Lancet, 1965:827-830.
  • 2[2]Fussey S, Guest JR, James O, et al. Identification and analysis of the major M2 autoantigens in primary billiary cirrhosis. Proc Natl Acad Sci USA, 1988, 85:8654-8658.
  • 3[3]Klein R, Berg PA. Significance of antimitochondrial antibody profiles in primary biliary cirrhosis. In: Lindon KD, Heathcote EJ, Poupon R, eds. Primary biliary cirrhosis: From pathogenesis to clinical treatment. Dordrecht, Netherland, Kluser Academic Pub, 1998. 24-34.
  • 4[4]Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxacid dehydrogonase complexes in primary biliary cirrhosis. Semin Liver Dis, 1997, 17:49-60.
  • 5[5]Leung PSC, Coppel RL, Ansari A, et al. Antimitochondrial antibodies in primary billiary cirrhosis. Semin Liver Dis, 1997, 17:61-69.
  • 6[6]Sherlock S, Dooley J. Diseases of the liver and biliary system. 11 th ed. Oxford UK, Blackwell Science, 2002. 242.
  • 7[7]Zein CO, Boe GM, Donlinger J, et al. The role of liver biopsy in the diagnosis of primary biliary cirrhosis. Hepatology, 2001, 34: pt2,343A.
  • 8Heathcote E.Management of primary biliary cirrhosis.The American Association for the Study of liver disease practice guidelines.Hepatology,2000,31(4):1005-1013.
  • 9Poupon RE,Bonnand AM,Chretien Y,et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.Hepatology,1999,29(6):1668-1671.
  • 10Lazaridis KN,Gores G J,Lindor KD.Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders.J Hepatol,2001,35 (1):134-146.

共引文献33

同被引文献24

  • 1施健,刘苏,陈伟忠,曾欣,陈岳祥,杨秀疆,谢渭芬.中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的系统评价[J].中华消化杂志,2005,25(6):355-358. 被引量:30
  • 2戴善梅,邢益平,董莉,王瑞云.优思弗治疗原发性胆汁性肝硬化的疗效观察[J].实用临床医学(江西),2006,7(10):59-60. 被引量:7
  • 3赵素贤,赵景民.原发性胆汁性肝硬化发病机制的研究进展[J].临床肝胆病杂志,2007,23(5):395-397. 被引量:17
  • 4Heathcote EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J]. Hepatology,2000,31 ( 4 ) : 1005-1013.
  • 5Maggiore, Dattolo P, Piaeenti M, et al.Thermal balance and dialysishypotension.Int J Artif Organs, 1995,18 ( 9 ): 518.
  • 6Dahlan Y, Smith L, Simmonds D, et al. Pediatric onset primary biliary cirrhosis[J]. Gastroenterology, 2003, 125: 1476-1479.
  • 7Kumagi, Heathcote EJ. Primary biliary cirrhosis[J]. Orphanet J Rare Dis, 2008, 3: 1.
  • 8Leung PS, Coppel RL, Gershwin ME. Etiology of primary biliary cirrho- sis: the search for the culprit[J]. Semin Liver Dis, 2005, 25: 327-336.
  • 9何菡.熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效观察[J].中国保健营养,2014,24(4中旬刊):1.
  • 10Pares A, Rodes J. Treatment of primary biliary cirrhosis [J]. Minerva Gastroen terol Dietol, 2000(46): 165-174.

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部